This is not the most recent version of the article. View current version (11 JUL 2012)

Intervention Review

Colloid solutions for fluid resuscitation

  1. F Bunn,
  2. P Alderson,
  3. V Hawkins

Editorial Group: Cochrane Injuries Group

Published Online: 20 JAN 2003

DOI: 10.1002/14651858.CD001319

How to Cite

Bunn F, Alderson P, Hawkins V. Colloid solutions for fluid resuscitation. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD001319. DOI: 10.1002/14651858.CD001319.

Author Information

*Ms Frances Bunn, Research Fellow, Centre for Research in Primary and Community Care (CRIPACC), University of Hertfordshire, College Lane, Hatfield, Hertfordshire, AL10 9PN, UK.

Publication History

  1. Publication Status: Commented
  2. Published Online: 20 JAN 2003


This is not the most recent version of the article. View current version (11 JUL 2012)



  1. Top of page
  2. Abstract
  3. Synopsis


Colloids are widely used in the replacement of fluid volume. However doubts remain as to which colloid is best. Different colloids vary in their molecular weight and therefore in the length of time they remain in the circulatory system. Because of this and their other characteristics, they may differ in their safety and efficacy.


To compare the effects of different colloid solutions in patients thought to need volume replacement.

Search strategy

We searched the Cochrane Injuries Group specialised register, the Cochrane Controlled Trials Register (2002 Issue 3), MEDLINE (1994-2002/07), EMBASE (1974-2002 August week 1), and the National Research Register (2002 issue 3). Bibliographies of trials retrieved were searched, and drug companies manufacturing colloids were contacted for information. The search was last updated in September 2002.

Selection criteria

Randomised and quasi-randomised trials comparing colloid solutions in critically ill and surgical patients thought to need volume replacement. The main outcomes measured were death, amount of whole blood transfused, and incidence of adverse reactions.

Data collection and analysis

Two authors independently extracted the data and assessed the quality of the trials.

Main results

Fifty-seven trials met the inclusion criteria, with a total of 3659 participants. Quality of allocation concealment was judged to be adequate in 20 trials and poor or uncertain in 37.

Deaths were obtained from 36 trials. For albumin or PPF versus hydroxyethyl starch (HES) 20 trials (n=1029) reported mortality. The pooled relative risk (RR) was 1.17 (95% CI 0.91, 1.50). For albumin or PPF versus gelatin four trials (n=542) reported mortality. The RR was 0.99 (0.69, 1.42). For gelatin vs HES 11 trials (n=945) reported mortality, RR was 1.00 (0.78,1.28). RR was not estimable in the albumin vs dextran, gelatin vs dextran, and HES vs dextran groups.

Thirty-six trials recorded the amount of blood transfused, however quantitative analysis was not possible due to skewness and variable reporting. Fifteen trials recorded adverse reactions, but none occurred.

Authors' conclusions

From this review, there is no evidence that one colloid solution is more effective or safe than any other, although the confidence intervals are wide and do not exclude clinically significant differences between colloids. Larger trials of fluid therapy are needed if clinically significant differences in mortality are to be detected or excluded.



  1. Top of page
  2. Abstract
  3. Synopsis

Plain language summary

No strong evidence to be certain of the safety of any particular type of colloid solution for replacing blood fluids

When a person is bleeding heavily, the loss of fluid volume in their veins can lead to shock, so they need fluid resuscitation. Colloids and crystalloids are two types of solutions used to replace lost blood fluid (plasma). They include blood and synthetic products. Both types appear to be similarly effective at resuscitation, but one type of colloid (human albumin) was found by another Cochrane review to increase deaths. Different colloids may have different effects. However, the review of trials found there is not enough evidence to be sure that any particular colloid is safer than any other